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PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma.  
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Abstract 
 
PAX2 is a homeobox transcription factor with fundamental roles in the embryogenesis of 
hindbrain and urinary tract. PAX genes are protooncogenes and it has been suggested that 
PAX2 contributes to the pathogenesis of renal cell carcinoma. Due to their expression in the 
developing hindbrain and their essential role in cerebellar development, it has been 
hypothesized that PAX2 and PAX5 may be involved in medulloblastoma tumorigenesis. 
Interestingly, PAX5 is re-expressed in most medulloblastomas. However, we have previously 
shown that overexpression of Pax5 is not sufficient for medulloblastoma formation in mouse 
models. We here investigated the expression pattern of PAX2 and several other genes of 
neuronal lineage in medulloblastoma and glioma cell lines. We found high expression of 
PAX2 mRNA and PAX2 protein in medulloblastoma cells and some glioma cell lines 
independent of neuronal differentiation. Gene suppression of PAX2 decreased the expression 
of the PAX2 transcriptional target GDNF and had a profound cytotoxic effect in vitro. 
Expression of PAX2 was then assessed in two separate medulloblastoma tissue microarrays 
with a total of 61 patient samples by immunohistochemistry. PAX2 expression was detected in 
the majority of medulloblastoma samples and was correlated with less differentiated 
histology. Therefore, PAX2 is a biomarker of more aggressive medulloblastoma and may 
represent a novel therapeutic target.  
 
208 words 
Introduction 
 
The paired box transcription factor gene family has been well characterized both in human 
(PAX) and mouse (Pax) and consists of nine genes in the human genome which encode the 
corresponding transcription factors (PAX/Pax)1. Every PAX gene encodes one transcription 
factor which contains the characteristic DNA binding paired domain. The PAX genes can be 
divided into four subgroups according to sequence homologies: PAX1/PAX9, 
PAX2/PAX5/PAX8, PAX3/PAX7 and PAX4/PAX62, 3. 
PAX genes, like other developmental control genes, are proto-oncogenes4, 5. They serve to 
orchestrate the expression of target gene responses that enable proliferation and suppress 
apoptosis in their target tissues6. The expression patterns of PAX genes are therefore tightly 
regulated both in a spatial and temporal manner during embryonal development. PAX2, in 
particular, is important for hindbrain and renal development. Interestingly, in hindbrain 
development, the closely related paralogous PAX genes (PAX2, 5 and 8), can compensate for 
the loss of one another and a major cerebellar phenotype occurs when two alleles are lost, i.e., 
five out of the six alleles are necessary7, 8. In general, PAX genes are downregulated in 
differentiated tissues9, 10. In particular, expression of PAX2, PAX5 and PAX8 is suppressed in 
postnatal hindbrain. Nevertheless, expression of some PAX genes is maintained postnatally in 
specific tissues. PAX4 and PAX6 are expressed in exocrine cells of the pancreas11-13, PAX6 is 
expressed in the cerebellum14 and PAX8 in the thyroid gland11, 15. The suppression of p53 
expression by PAX2, PAX5 and PAX8 by binding to the 5´ regulatory unit of the human p53 
gene is one example of the mechanisms involved in control of growth and cell death by PAX 
genes16.  
In line with their biological functions, deregulated expression of PAX genes can drive the 
development of tumors in children and adults. Specifically, fusion genes involving PAX3 or 
PAX7 cause alveolar rhabdomyosarcoma17-19. An oncogenic fusion gene involving the IG 
enhancer and PAX5 has been found in malignant B-cell lymphomas20, 21. PAX8 can also be 
involved in a translocation which results in the PAX8-PPARγ fusion protein, which is 
frequently found in follicular thyroid carcinoma22. Elevated PAX2 expression has been found 
in cystic and hyperproliferative disorders of the kidney, possible predecessors of renal cell 
carcinoma10, 23, 24. Genetic alterations like point mutations and translocations have been 
described in kidney hypoplasia and the coloboma-kidney syndrome25-28. A high proportion of 
primary renal cell carcinomas expressed PAX 29. It is known that an elevated expression of 
PAX2 mitigates cisplatin-induced cytotoxicity and blocks caspase-2 induced apoptosis in 
ACHN and CAKI-1 renal carcinoma and human embryonic kidney 293 (HEK293) cells30, 31. 
Accordingly, inhibition of PAX2 with specific siRNAs in the cell lines EJ (bladder carcinoma) 
and IGROV-1 (ovarian carcinoma) increased the rate of apoptosis thereby lowering the 
proliferation rate32. The same effect was seen in immortalized rat proximal tubulus cells33.  
Due to the expression pattern of PAX2, PAX5 and PAX8, particular interest has been 
generated in these genes as candidate genes involved in the genesis of medulloblastoma, the 
most common malignant embryonal brain tumors that originates from the hindbrain. 
Interestingly, PAX5 is re-expressed in most medulloblastomas in contrast to differentiated 
cerebellum tissue14. However, overexpression of Pax5 by retroviral transfer to embryonic 
neuroectodermal precursor cells or in the granule cell layer of engrailed2-Pax5 transgenic 
mice was not sufficient for medulloblastoma formation34. We therefore here investigated the 
expression pattern of PAX2 and PAX8 in addition to PAX5 in medulloblastoma cells and 
compared it to their expression in glioma cells, in which expression of PAX5 has been shown 
to correlate inversely with the expression of p5316. We found high expression of PAX2 in 
medulloblastoma cells and the majority of medulloblastoma samples from two separate tissue 
microarrays. Gene suppression of PAX2 had a profound cytotoxic effect in vitro. 
 
Material and methods 
 Cell culture 
Daoy medulloblastoma cells were a gift from T. Pietsch (Bonn, Germany). The human 
malignant glioma cell lines were kindly provided by N. de Tribolet (Lausanne, Switzerland). 
The murine glioma cell line SMA560 was a gift of D. D. Bigner (Durham, NC, USA). The 
immortalized astrocytic cell line SV-FHAS was kindly provided by A. Muruganandam 
(Ottawa, Canada). All cells were maintained in DMEM containing 10% fetal calf serum 
(Biochrom KG, Berlin, Germany), 2mM glutamine and 100IU/ml penicillin/100µg/ml 
streptomycin (Life Technologies, Karlsruhe, Germany).  
Glioma cell lines were stably transfected by lipofection using FuGene6 (Roche, Mannheim, 
Germany). The plasmids encoding human PAX2b or PAX2c (pCMV/PAX2-N1 and 
pCMV/PAX2-N3 respectively plus the empty control vector pHN/CMV) were kindly 
provided by M. Eccles (Otago, New Zealand)35, 36. The plasmid encoding murine Pax2 
(pmPax2/334 plus the empty vector pKW10) was kindly provided by M. Busslinger (Vienna, 
Austria). At 48 h after transfection, the cells were shifted to medium supplemented with G418 
sulphate (1 mg/ml) or puromycin (2 mg/ml). For all experiments, pooled transfectants rather 
than single clones were used. 
For transient gene suppression of human PAX2, a small interfering RNA (siRNA) was 
employed (Thermo Fisher Scientific, Dharmacon Products, Lafayette, CO, USA). The 
following sequences targeting the human PAX2 coding region were used: d1: 5′-
AAACUGUCCACACCACUCUUU-3′; d2: 5′-UCUGAUUUGAUGUGCUCUGUU-3′. A 
predesigned scrambled siRNA was used as control (Thermo Fisher Scientific, Dharmacon 
Products, Lafayette, CO, USA). For transient siRNA transfections Metafectene Pro was 
employed according to the protocol with a final siRNA concentration of 50nM and 0.33µl 
Metafectene Pro in 100µl transfection medium per well for 96-well plates. 
Cell growth was assessed by crystal violet staining as previously described37. Cell viability 
was analysed by lactate dehydrogenase (LDH) release assays38. For the detection of 
chemotherapy-induced cell death, the cells were plated on 96 well plates (Falcon, Becton-
Dickinson) at 1.5 x 104/well and allowed to attach overnight. Then the cells were incubated  
with chemotherapeutics for 72 hours in serum-free medium and stained with crystal violet. 
Alternatively cell viability was measured by flow cytometry: First cells were washed with ice-
cold PBS, stained with 5µg/ml propidium iodide (PI) in PBS and then analysed by flow 
cytometry. For cell cycle analysis, detached cells were harvested from the supernatant by 
centrifugation and added to the non-detached cells harvested by trypsination. The cells were 
washed with phosphate-buffered saline, fixed in 70% ice-cold ethanol, centrifuged, washed 
with phosphate-buffered saline again, stained with propidium iodide (50 µg/ml) diluted in 
phosphate-buffered saline containing RNase A (100 µg/ml) and subjected to flow cytometric 
analysis of DNA content using Dako CyAn Cytometer. Percentages of sub-G1 cells were 
calculated using the Dako Summit software (Dako, Glostrup, Denmark).  
 
Real-time PCR 
 
RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Superscript II RT 
(Gibco, Life Technologies, Carlsbad, CA, USA) was employed for cDNA synthesis. cDNA 
amplification was monitored using SYBR Green chemistry (ABgene, Epsom, UK) on the ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems, Weiterstadt, Germany). The 
conditions for all PCR reactions were as follows: 40 cycles of 95°C for 15s and 60°C for 1 
min, using the following specific primers (forward and reverse): 18S: 5´-
CGGCTACCACATCCAAGGAA-3´, 5´-GCTGGAATTACCGCGGCT-3´; DLX1: 5´ 
TGGAATCCGAACTCCTCATC-3´, 5´- TCACATCAGTTGAGGCTGCT-3´; EMX2: 5´- 
AGCTTCTAAGGCTGGAACACGC-3´; 5´- TACCTGAGTTTCCGTCAGGCTG-3´; hASH1: 5´- 
AGGAGCTTCTCGACTTCACCAA-3´; 5´-ATCACCCTGCTTCCAAAGTCC-3´; NGN2: 5´- 
AGAGCCAACTAAGATGTTCGTCAAA-3´; 5´- CCGATCCGAGCAGCACTAAC-3´; OLIG2: 5´- 
AACTCCTCCACGTGCTTCCTG-3´; 5´- CGGTGCGATCAGAGGAAGG-3´; PAX2: 5´-
TGTGGACAGTTTGCGGAAGCA-3´, 5´-TGATGTGCTCTGATGCCTGGAA-3´; PAX5: 
5´-AAGCGCAAGAGAGACGAAGGT-3´, 5´-TGAACAAGTCTCCCCGCATC-3´; PAX6 : 
5´-GACTTCGGTGCCAGGG-3´ , 5´-TGGTATTCTCTCCCCCTCCTT-3´; PAX8 : 5´-
ACAAACGCCAGAACCCTACCAT-3´, 5´-TTAATGGAGCTGACACTGGGCA-3´. 
Relative mRNA levels were calculated by 2(-Delta Delta C(T)) Method39. 
 
Immunoblot analysis 
 
Cells were washed with ice-cold PBS and harvested into ice-cold PBS containing protease 
inhibitors. Cellular lysates were prepared as described40 and subjected to SDS-PAGE analysis. 
Equal loading was ascertained by Ponceau S staining. Membranes were probed with 
polyclonal rabbit anti-human PAX2 antibodies (Cat. No. 71-6000, Invitrogen Corporation, 
Life Technologies, Carlsbad, CA, USA) or goat anti-ß-actin (SC-1616, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The secondary anti-rabbit and anti-goat antibodies 
were purchased from Santa Cruz Biotechnology. Enhanced chemiluminescence (ECL+) 
(Amersham, Little Chalfont, UK) was used for detection. 
 
Induction of hypoxia 
 
Hypoxia was induced by incubating cells in Gas Pak pouches for anaerobic culture (Becton 
Dickinson, Heidelberg, Germany)40. Briefly, the cells were plated on 96 well plates at 2 x 
104/well and allowed to attach overnight. Then the cells were incubated in serum-free DMEM 
without glucose (Gibco BRL, Basel, Switzerland) adjusted to 2 mM glucose under normoxia 
or hypoxia for the indicated time periods. Equal cell densities were ensured by crystal violet 
staining when comparing cells expressing vehicle and PAX2b, PAX2c or murine Pax2. Cell 
death was assessed by means of LDH release assay. 
 
Animal studies 
 
VMdK mice were anesthetized and placed in a streotactic fixation device (Stoelting, Wood 
Dale, IL, USA). 5,000 SMA560 cells stable transfected with vehicle or murine Pax2, were 
injected into the right striatum. The mice were sacrificed when developing neurological 
symptoms. All animal research was carried out in accordance with the law for treatment of 
animals in Germany and approved by the local authorities (N3/03, Regierungspräsidium 
Tübingen, Germany). 
 
Human tissue specimens 
 
We investigated two independent tissue microarrays containing medulloblastoma specimens 
of 61 patients and 3 normal appearing cerebellar specimens from the tumor banks of the 
departments of neuropathology of the University of Frankfurt (n=18) and Münster (n=43). All 
tissues were evaluated by at least two neuropathologists according to the current classification 
of tumours of the central nervous system41 using routine HE, reticulin and 
immunohistochemical stainings including antibodies against Ki-67, GFAP, MAP2, NeuN, 
synaptophysin and vimentin.  
 
Cell pellets for immunocytochemistry 
 
The human medulloblastoma and glioma cell lines cells were maintained in DMEM 
containing 10% FCS and penicillin (100 IU/mL)/streptomycin. 50 million cells of each cell 
line were detached using Accutase, centrifuged for 5 min at 1000 U/min. Cell pellets were 
fixed in 4% buffered formalin (pH 7.4) for 24 paraffin-embedded afterwards.  
 
Immunohistochemistry 
 
All human tissue specimens were fixed in 4% buffered formaline (pH 7.4), embedded in 
paraffin, cut with a microtome (3µm thickness) and placed on SuperFrost Plus slides (Microm 
International, Walldorf, Germany). For immunohistochemistry, the following antibody was 
used: polyclonal rabbit anti-human PAX2 (Invitrogen Corporation, CA, USA). Establishment 
of the immunostainings was performed on full mount sections whereas for statistical analysis 
a tissue micro array (TMA) consisting of all human medulloblastoma samples was 
investigated. Tissue labelling for PAX2 was performed using DiscoveryXT 
immunohistochemistry system (Ventana, Strasbourg, France). A cell conditioning 
pretreatment was performed for 44 min. After a 4 min blocking step with inhibitor D 
(Ventana, Strasbourg, France) the primary antibody was applied at 1:50 for 32 min followed 
by a 28 min incubation with one drop of I-View-Biotin Ig (Ventana). An avidin and a biotin 
blocker was applied to the samples for 4 min. For diaminobenzidine (DAB) visualization, the 
sections were incubated with one drop of I-View SA-HRP for 16 min and then with 
DAB/H2O2 for additional 8 min. The sections were finally incubated with a copper enhancer 
(Ventana) for 4 min, washed, counterstained with hematoxylin and mounted. 
 
Immunocytochemistry 
 
All cell pellets were cut with a microtome (3µm thickness) and placed on SuperFrost Plus 
slides (Microm International, Walldorf, Germany). Immunocytochemical PAX2 staining was 
performed using the same protocol as for the immunohistochemical analysis. Additionally cell 
pellets were stained for GFAP, MAP2, NeuN, vimentin and synaptophysin. 
 
Tissue microarray evaluation 
Immunostained sections were evaluated by 2 examiners (PB and MM). A semi-quantitative 
score including staining intensity and frequency similar to commonly used scores in routine 
pathology was applied42. The frequency score ranged from 0-4 (Score=0, 0-1%; score=1, 1-
10%; score=2, 10-25%; score=3, 25-50% and score=4, >50% of all cells showing a positive 
staining). The intensity score ranged from 0-3 (0, no staining; score=1, weak staining; 
score=2, moderate staining and score=3, strong staining). The two results for staining 
intensity and frequency were multiplied, so that a “Multi-Score” reflected both. 
 
Statistical analysis 
Where indicated, analysis of significance was performed using the two-tailed Student t test 
with P < 0.05 considered significant and P < 0.01 considered highly significant (Excel; 
Microsoft, Seattle, WA, USA). Evaluation of survival patterns in mice bearing intracerebral 
gliomas was performed by the Kaplan-Meier method. 
Contingency analysis for PAX2 expression scores derived from the the tissue microarray 
studies according to histomorphological subtypes was performed followed by Pearsons Chi 
square test. JMP IN 8.0 (SAS Institute, Cary, NC, USA) was used for statistical analysis.  
 
 
 
 
Results 
 
PAX2 is highly expressed in Daoy human medulloblastoma cells and some malignant 
human glioma cell lines. 
 
To investigate the pattern of expression of PAX2, PAX5 and PAX8 we first screened the 
human medulloblastoma cell line Daoy and a panel of established human malignant glioma 
cell lines by means of quantitative RT-PCR (qPCR). High PAX2 mRNA levels were found in 
Daoy cells as well as in the glioma cell lines T98G and A172 (Fig. 1A). These results were 
confirmed by western blot analysis and immunohistochemistry of cytopellets (Fig. 1A). In 
contrast, PAX5 mRNA expression was restricted to the medulloblastoma cell line Daoy (Fig. 
1B). PAX8 was not detectable in Daoy cells, but five out of twelve glioblastoma cell lines 
showed PAX8 mRNA expression (Fig. 1C). We also investigated the mRNA expression of 
PAX6, whose expression in normal human brain, gliomas and medulloblastomas has been 
described previously14, 43 and confirmed low levels of expression of PAX6 in Daoy cells, all 
glioma cell lines as well as the immortalized astrocytic cell line SV-FHAS (data not shown). 
 
Overexpression of PAX2 has no effect on proliferation rate or sensitivity against 
chemotherapeutic agents and hypoxia in human LNT-229 glioma cells. 
 
Because overexpression of PAX2 has a well characterized oncogenic function in renal 
carcinoma32 we introduced PAX2 into non-expressing glioma cell lines in order to conduct 
functional experiments. Stable transfectants were established in A172, LN-18, LNT-229 and 
U88MG cells with the PAX2 isoforms PAX2b and PAX2c or the control vector coding for 
neomycin resistance (neo). Representative western-blots from LNT-229 PAX2b and PAX2c 
cells are shown in Fig. 2A. However, in contrast to published effects in some other cell 
lines30, 32, no effect on proliferation (Fig. 2B) or sensibility against the chemotherapeutic 
drugs cisplatinum (Fig. 2C) and vincristin (Fig. 2D) were found in the transfectants as 
assessed by crystal violet assay. These experiments also were performed without FCS and 
with cell densities of 500 and 5,000 cells per well (data not shown).  
Because it is increasingly recognized that in the glioblastoma microenvironment cell death is 
mainly necrotic and hypoxia resistance is highly relevant for therapy, we also investigated the 
effect of PAX2 overexpression in a paradigm of hypoxia-induced cell death that closely 
mimics the mode of cell death observed in vivo44. However, there was no significant 
difference in hypoxic cell death in LNT-229 PAX2 cells compared to neo cells  
(Fig. 2E). Under normoxic conditions, the rates of spontaneous cell death were low in both 
PAX2 and neo cells (Fig. 2F). Immunocytochemistry of cell pellets for neuronal and glial 
markers (GFAP, vimentin, NeuN, synaptophysin and MAP2) did not reveal an effect of PAX2 
overexpression in LN-18, LNT-229 and T98G glioma cell lines or a difference between 
glioma cell lines positive for PAX2 versus those lacking PAX2 expression (data not shown). 
 
Stable Pax2 overexpression has no effect on proliferation rate or sensitivity against 
chemotherapeutic agents and hypoxia in murine SMA560 glioma cells. 
 
Because some oncogenic properties are only evident in the in vivo situation, the syngenic 
orthotopic mouse model of SMA560 glioma cells in VMDk mice was employed. After 
transfection of murine Pax2 into SMA560 mouse glioma cells stable overexpression was 
achieved (puro). Additionally to the amount of Pax2 already being expressed intrinsically 
further Pax2 expression is seen at the 47kDa band in Pax2 transfected cells. The unspecific 
bands at 36 and 42kDa respectively do not change in intensity compared to puro control cells 
(Fig. 3A). In vitro, growth curves (Fig. 3B), chemosensitivity (Fig. 3C, D) and susceptibility 
towards hypoxia (Fig. 3E, F) were unaltered by Pax2 similar to the results with human 
glioma cell lines. We then compared symptom free survival of syngenic VMDk mice after 
intracranial inoculation of 5,000 SMA560 cells stably transfected with Pax2 versus puro 
control cells. However no difference in symptom free survival between tumor implants of the 
two groups could be observed (Fig. 3G). To rule out a differing ability of the SMA560 puro 
versus Pax2 transfected cells to engraft, a clonogenity assay has been performed. 500 cells per 
well were seeded into a six well plate and incubated for 96 hours. We demonstrated that the 
same amount of cells adhered to the bottom of the well and were able to form vial colonies 
(data not shown). 
 
Efficient and specific gene suppression by PAX2 targeted siRNAs d1 and d2 of PAX2 in 
Daoy and T98G cells. 
Transient transfection of Daoy and T98G cells with PAX2 targeted siRNA d1 and d2 
compared to scr control siRNA, transfection or growth medium alone was performed. 
The specificity of the siRNAs was demonstrated by co-suppression of the PAX2 target gene 
GDNF45 as well as PAX2 itself in Daoy medulloblastoma cells stably overexpressing PAX2b 
(Fig. 4A, B), while GFAP, nestin, NSE and vimentin which are not known to be PAX2 targets 
were not regulated (data not shown). As in Daoy cells rapid cell death was occurring 
following PAX2 downregulation we were not able to show the effect on PAX2 protein level in 
this cell line. Instead we employed the glioma cell line A172, where the effect on cell survival 
was less pronounced and the bladder carcinoma cell line EJ32 to show the effect on PAX2 
protein level. Efficient gene suppression in these two cell lines was demonstrated by western 
blot analysis (Fig. 4C). 
 
Gene suppression of PAX2 induces cytotoxic effects in Daoy and T98G cells. 
 
Transient transfection of Daoy cells with PAX2 targeted siRNA d1 and d2 compared to scr 
control siRNA, transfection or growth medium alone had profound cytotoxic effects as shown 
by crystal violet assay and phase contrast photography (Fig. 5A, B). Flow-cytometric analysis 
after PI-staining demonstrated an elevated rate of cell death occurring in cells treated with 
PAX2 specific siRNA. Cell Cycle analysis employing flow cytometry showed an elevated 
sub-G1 peak indicating apoptosis as well as a decreased number of cells in S- and M-phase 
(Fig 5C). A similar effect was observed in T98G malignant human glioma cells (Fig. 5D-F).  
 
PAX2 expression is restricted to basket cells in the normal cerebellum and increases with 
the degree of malignancy in medulloblastomas. 
 
Because the biologic function of PAX2 in hindbrain development and the published data on 
deregulated PAX5 expression in medulloblastomas as well as our in vitro data strongly 
suggested a role for PAX2 in medulloblastomas, we investigated expression of PAX2 protein 
in medulloblastoma samples from two separate tissue microarrays. 
We found that in the normal cerebellum, PAX2 expression was largely absent. However, 
basket cells commonly had nuclear PAX2 expression (Fig. 6A). In medulloblastomas, nuclear 
PAX2 expression significantly increased with a less differentiated histomorphological 
phenotype. While virtually all highly differentiated desmoplastic/nodular medulloblastomas 
remained PAX2 negative (Fig. 6B), intermediate nuclear PAX2 levels were observed in the 
classic subtype (Fig. 6C). The medulloblastoma with the least differentiated phenotype, 
mainly the anaplastic subtype, strongly exhibited nuclear PAX2 expression (Fig. 6D). The 
statistical analysis of PAX2 expression related to the medulloblastoma subtypes revealed 
significant differences (p<0.005 in Pearsons Chi square test) showing highest PAX2 levels in 
medulloblastomas with the lowest histological degree of differentiation and lowest levels in 
medulloblastomas with higher differentiated morphology (Fig 6E).  
 PAX2 expression in gliomas: in silico analyses and correlation with markers of neuronal 
lineage differentiation. 
 
In contrast to medulloblastoma, the expression of PAX2 was observed in only a small 
minority of glioma cell lines. To elucidate possible mechnisms of PAX2 expression in 
gliomas, we followed a candidate gene approach and did in silico analyses of glioma mRNA 
profiling datasets. With the candidate gene approach, we tested the hypothesis that PAX2 was 
part of a neuronal signature. Therefore expression of markers known to be involved in 
neuronal differentiation was investigated in the panel of glioma cell lines, Daoy cells and SV-
FHAS cells by qRT-PCR. The data are summarized in Table 1. While several of the neuronal 
markers were highly expressed in gliomas congruent with the increasing awareness of 
neuronal features in gliomas46, no correlation of PAX2 with these markers became apparent. 
We also established immunohistochemistry on cell pellets of Daoy medulloblastoma and the 
twelve glioma cell lines as well as the stable PAX2 transfectants used in our study to assess 
GFAP, MAP2, NeuN, vimentin and synaptophysin protein expression. However, we observed 
no difference between PAX2 positive and negative cell lines or between PAX2 overexpressing 
cell lines and their controls (data not shown). In silico analyses were performed with the 
Oncomine registry. According to the Pomeroy gene expression analysis, PAX2 was 1,889 fold 
upregulated in classic medulloblastoma samples compared to normal cerebellum probes. 
GDNF as a PAX2 target gene was upregulated 2,569 fold in classic medulloblastoma samples 
(Fig. 5B). In gliomas, no significant correlation with neuronal markers defining subclasses of 
high-grade glioma46 was apparent. Moreover, PAX2 was not inversely correlated with p53 
mRNA levels (data not shown).  
 
 
Discussion 
 
Our study demonstrates that PAX2 is aberrantly expressed in medulloblastoma and glioma 
cell lines. In particular, the medulloblastoma cell line Daoy expressed PAX2, PAX5 and PAX6 
but not PAX8. Out of twelve glioma cell lines two aberrantly expressed PAX2, while five 
others showed PAX8 expression in a complementary pattern (Fig. 1). Only five glioblastoma 
cell lines tested neither expressed PAX2 nor PAX8. This is noteworthy, since it has long been 
established that the three members of the paralogous PAX2/5/8 group can compensate for 
each other in the embryogenesis of the midbrain and cerebellum47 as well as the inner ear 
development48. Interestingly, in PAX2 negative cell lines, PAX2 overexpression did not 
enhance growth, reduce sensitivity against the chemotherapeutic agents cisplatin and 
vincristine or alter resistance towards hypoxia (Fig. 2). Neither was asymptomatic survival 
time of syngenic VMdK mice after intracerebral inoculation with SMA560 cells affected by 
transfection with murine Pax2 (Fig. 3G). In contrast, by transiently transfecting Daoy 
medulloblastoma and T98G glioma cell line with PAX2 specific siRNA molecules we could 
induce a high level of cell death and a marked effect on proliferation (Fig. 5). This suggests 
that only the subgroup of tumors which aberrantly maintains PAX2 expression benefits from 
its antiapoptotic functions whereas the other group relies on alternative mechanisms to evade 
cell death. It is intriguing to speculate about different tumor stem cell populations with or 
without PAX2 gene expression as the mechanism of this dichotomy, but there are no data 
available to test this hypothesis. PAX2 expression may also serve to compensate for PAX6 
expression and its known tumor suppressor properties, since it has been shown that Pax2 and 
Pax6 repress each other and their target genes49 and we found PAX6 expression in Daoy cells 
and all 12 glioma cells investigated (Table 1). 
The cyototoxic effect of PAX2 gene expression in the PAX2-dependent cell lines is congruent 
with other work demonstrating a potent antiapoptotic function of PAX proteins in some 
melanoma, ovarian, bladder and prostate carcinoma cell lines32, 50-52. The specifity of the 
PAX2 knockdown is supported by its effect on GDNF, a known target gene of PAX2, which is 
suppressed by PAX2 siRNA (Fig. 4). In silico analysis of the Oncomine registry demonstrated 
that PAX2 expression is elevated in medulloblastoma compared to normal cerebellum. 
However, neither our analysis of candidate genes (Table 1) nor in silico analysis (data not 
whown) were able to identify a neuronal signature correlating with PAX2 expression. 
Therefore, there is not an obvious role of PAX genes in the evolution of the neuronal 
phenotype in gliomas.  
Finally, to explore the clinical value of PAX2 as a marker of medulloblastoma, we 
investigated the expression of PAX2 protein in two tissue microarrays (TMA) containing 61 
medulloblastoma samples. The TMA analysis confirmed aberrant PAX2 expression in 
medulloblastoma samples, while in normal cerebellum PAX2 expression was restricted to 
basket cells (Fig 6 A-D). Importantly, the expression of PAX2 was associated with 
histomorphological dedifferentiation, as medulloblastomas with the lowest histological degree 
of differentiation showed higher PAX2 expression than medulloblastomas with better 
differentiation (Fig. 6 E). This is a finding of considerable interest. Therefore, the prognostic 
and predictive value of PAX2 expression should be validated in prospective studies of 
medulloblastoma.  
 
In summary, PAX2 represents a biomarker of more aggressive medulloblastoma and may have 
potential as a novel therapeutic target. 
 
 
 
 
 
 
Figure legends 
 
Fig. 1. PAX2 is highly expressed in Daoy human medulloblastoma cells and some malignant 
human glioma cell lines. 
mRNA from Daoy medulloblastoma cells and a panel of 12 glioma cell lines plus SV-FHAS 
was investigated for expression of PAX2 (A), PAX5 (B) and PAX 8 (C) mRNA by RT-
quantitative PCR. PAX2 expression on the protein level was confirmed by western-blotting 
and immunohistochemistry (A). 
 
Fig. 2. Proliferation and sensitivity against chemotherapeutic agents and hypoxia are not 
affected by overexpression of PAX2 in human LNT-229 glioma cells. 
(A) Stable PAX2 expression after transfection of vectors coding for PAX2b and PAX2c was 
verified by western-blotting. (B) Growth rate of LNT-229 cells overexpressing PAX2b or 
PAX2c compared to neo control cells as measured by crystal violet assay and normalized to 
the time point 24 hours after seeding. Sensitivity of LNT-229 cells overexpressing PAX2b or 
PAX2c compared to neo control cells against different concentrations of the chemotherapeutic 
agents cisplatin (C) and vincristin (D) 72 hours after addition. Hypoxia-induced cell death in 
LNT-229 cells overexpressing PAX2b or neo control cells after 16 hours of hypoxia (0,1% 
oxygen, 20,000 cells per well in a 96-well plate) (E) compared to normoxia (F), LDH release 
assay. 
 
Fig. 3. Stable Pax2 overexpression does not alter survival in syngenic mice carrying 
intracranial SMA560 glioma cell grafts. 
(A) Stable Pax2 over-expression after transfection of vectors coding for murine Pax2 was 
verified by western-blot. (B) Growth rate of SMA560 cells overexpressing Pax2 compared to 
puro control cells as measured by crystal violet assay and normalized to the time point 24 
hours after seeding. Sensitivity of SMA560 cells overexpressing Pax2 compared to puro 
control cells against different concentrations of the chemotherapeutic agents cisplatin (C) and 
vincristin (D) 72 hours after addition. LDH release of SMA560 cells overexpressing Pax2 or 
puro control cells after 16 hours of hypoxia (0,1% oxygen, 20,000 cells per well in a 96-well 
plate) (E) compared to normoxia (F). Survival time of VMdK mice inoculated with SMA560 
cells overexpressing Pax2 compared to puro control cells (G). 
 
Fig. 4. Efficient and specific gene suppression by PAX2 targeted siRNAs d1 and d2 in Daoy 
and T98G cells. 
(A) mRNA from Daoy cells overexpressing PAX2b and cotransfected with d2 PAX2 specific 
or scr scrambled siRNA was investigated for the level of PAX2 expression. (B) Specifity was 
verified by determination of mRNA expression of GDNF, a known target gene of PAX2. (C) 
PAX2 downregulation by d1 and d2 PAX2 specific siRNAs compared to scr scrambled siRNA 
in A172 glioma cells A172 and EJ bladder carcinoma cells shown by western-blot. See top 
lane for PAX2 at 47kDa and bottom lane for actin at 45kDa. 
 
Fig. 5. Gene suppression of PAX2 induces cytotoxic effects in Daoy and T98G cells. 
Effect of PAX2 specific siRNAs d1 and d2 compared to scrambled siRNA (scr), Metafectene 
Pro transfection reagent (MF) or growth medium alone (VM) on Daoy (A) and T98G (D) 
cells as shown by crystal violet assay. Light-microscopic aspect of Daoy (B) and T98G (E) 
cells transfected with PAX2 specific siRNA molecules (d2) compared to scrambled siRNA 
(scr) or Metafectene Pro transfection reagent (MF). Effects of transfection with d2 or scr 
siRNA on cell viability and proliferation measured by propidium iodide staining and flow 
cytometry in Daoy (C) and T98G cells (F). Elevation of PAX2 expression by the factor of 
1,889 (p=0.002) and GDNF as a PAX2 target gene by the factor of 2,569 (p=3.12E-4) in 
classic medulloblastoma samples compared to normal cerebellum probes according to 
Oncomine registry (Pomeroy brain dataset) (G). Expression levels are normalized to the log2 
median-centered intensity of the gene expression arrray. Boxed areas display the 75th 
percentile, the median and the 25th percentiles. Error bars delineate the 90th and 10th 
percentiles while the dots specify the maximum and minimum values. 
 
Fig. 6. PAX2 expression increases with the degree of malignancy in medulloblastomas. 
 (A) PAX2 immunohistochemistry in the normal cerebellum revealed that only basket cells 
(arrows) exhibit a strong nuclear PAX2 expression while other neuronal cells such as Purkinje 
cells (inset – arrowhead) or granular cells (inset – asterisk) remained completely negative. 
PAX2 expression in medulloblastomas varied according to the degree of differentiation 
showing lowest levels in desmoplastic (B) or nodular subtypes, intermediate levels in the 
classic medulloblastoma subtype (C) and strongest PAX2 expression in undifferentiated 
anaplastic (D) medulloblastomas (asterisk indicating tumor necrosis). (E) Statistical analysis 
of nuclear PAX2 expression according to the medulloblastoma subtype using contingency 
analysis showing the Multi-score proportions of PAX2 expression in medulloblastoma 
specimens. Ordinal scaled response variable (Multi-Score) and nominal explanatory variable 
(amount of specimens) were analysed with a contigency analysis (p<0.005 in Pearsons Chi 
square test). The area of one box is corresponding to the amount of specimen falling in the 
equivalent specific group of Multi-score analysis of PAX2 expression. 
 
Table 1. Homeobox and helix-loop-helix transcription factors in glioblastoma and 
medulloblastoma. 
Expression pattern of homeobox or helix-loop-helix transcription factors DLX1, EMX2, 
hASH1, NGN2 and OLIG2 compared to the expression of PAX2, PAX5, PAX6 and PAX8. 
The amount of expression on mRNA level was measured by qPCR and evaluated according to 
Muratovska et al.32 No correlation between the expression of PAX transcription factors and 
homeobox or helix-loop-helix transcription factors were observed. Furthermore no correlation 
existed with p53 status according to Ishii et al.53 (wt=wild-type; mt=mutant; nu=null). 
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